Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: In vitro and in vivo characterization

British Journal of Pharmacology

Volumn 118, Issue 6, 1996, Pages 1377-1384

  Delpy, Eric ^a   Le Monnier De Gouville, Anne Charlotte ^a  

^a Laboratoire GlaxoWellcome   (France)

Author keywords

Aortic ring; Cyclic GMP; DMPPO; Hypertension; PDE inhibitor; Phosphodiesterase 5; Vasorelaxation

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; ATRIAL NATRIURETIC FACTOR; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; GUANYLATE CYCLASE INHIBITOR; METHYLENE BLUE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENCY; HEART RATE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; URINALYSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0030004364     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15548.x     Document Type: Article

References (45)

1. ANAND-SRIVASTAVA, M.B. & TRACHTE, G.J. (1993). Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol. Rev., 45, 455-497.
2. BEAVO, J. (1990). Multiple phosphodiesterase isozymes: background, nomenclature and implications. In Molecular Pharmacology of Cell Regulation. ed. Beavo J. & Houslay M.D. Vol. 2, pp. 3-14. Chiester: John Wiley & Sons Ltd.
3. BOHLEN, H.G. (1979). Arteriolar closure mediated by hyperresponsiveness to norepinephrine in hyptertensive rats. Am. J. Physiol., 236, H157-H164.
4. BURNETT, J.C., KAO, P.C., HU, D.C., HESER, D.W., HEUBLEIN, D., GRANGER, J.P., OPGENORTH, T.J. & REEDER, G.S. (1986). Artrial natriuretic peptide elevation in congestive heart failure in the human. Science. 231, 1145-1147.
5. BUXTON, I.L.O. & BRUNTON, L.L. (1983). Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem., 258, 10233-10239.
6. CHRISTODOULIDES, N., DURANTE, W., KROLL, M.H. & SCHAFER, A.I. (1995). Vascular smooth muscle cell heme oxygenases generate guanylyl cyclase-stimulatory carbon monoxide. Circulation, 91, 2306-2309.
7. CORNWELL, T.L., PRYZWANSKY, K.B., WYATT, T.A. & LINCOLN, T.M. (1991). Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells. Mol. Pharmacol., 40, 923-931.
8. COSTE, H. & GRONDIN, P. (1995). Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol., 50, 1577-1585.
9. DUMAÎTRE, B.A. & DODIC, N. (1995). New pyrazolopyrimidine derivatives inhibit cyclic guanosine 3′5′-monophosphate specific phosphodiesterase-useful for treating angina, hypertension, congestive heart failure, renal failure, atherosclerosis etc. Patent Application, EP-636626-A1.
10. FULLE, H.J. & GARBERS, D.L. (1994). Guanylyl cyclase - a family of receptor-linked enzymes. Cell Biochem. Funct., 12, 157-165.
11. GARBERS, D.L. (1989). Guanylate cyclase, a cell surface receptor. J. Biol. Chem., 264, 9103-9106.
12. GERZER, R., HOFMAN, F. & SCHULZ, G. (1981). Purification of a soluble, sodium nitroprusside-stimulated guanylate cyclase from bovine lung. Eur. J. Biochem., 116, 479-486.
13. GILES, T.D., QUIROZ, A.C., ROFFIDAL, L.E., MARDER, H. & SANDER, G.E. (1991). Prolonged hemodynamic benefits from a high-dose bolus injection of human atrial natriuretic factor in congestive heart failure. Clin. Pharmacol. Ther., 50, 557-563.
14. GREENBERG, S.S., DIECKE, F.P.J., CANTOR, E., PEEVY, K. & TANAKA, T.P. (1990a). Inhibition of sympathetic neurotransmitter release by modulators of cyclic GMP in canine vascular smooth muscle. Eur. J. Pharmacol., 187, 409-423.
15. GREENBERG, S.S., DIECKE, F.P.J., PEEVY, K. & TANAKA, T.P. (1990b). Release of norepinephrine from adrenergic nerve endings of blood vessels is modulated by endothelium-derived relaxing factor. Am. J. Hypertens., 3, 211-218.
16. GRUETTER, C.A., GRUETTER, D.Y., LYON, J.E., KADOWITZ, P.J. & IGNARRO, L.J. (1981). Relationship between cyclic guanosine 3′:5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J. Pharmacol. Exp. Ther., 219, 181-186.
17. HAMET, P., PANG, S.C. & TREMBLAY, J. (1989). Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J. Biol. Chem., 264, 12364-12369.
18. HARRIS, A., LEMP, B., BENTLEY, R., PERRONE, M. & HAMEL, L. (1989). Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J. Pharmacol. Exp. Ther., 249, 394-400.
19. 1. J. Biol. Chem., 255, 5113-5119.
20. 2+ transients. Circ. Res., 69, 1369-1379.
21. IGNARRO, L. (1992). Heme-dependent activation of soluble guanylate cyclase by nitric oxide - A widespread signal transduction mechanism. Biochem. Soc. Trans., 20, 465-469.
22. IGNARRO, L.J. & KADOWITZ, P.J. (1985). The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Pharmacol. Toxicol., 25, 171-191.
23. KOMAS, N., LUGNIER, C. & STOCLET, J.C. (1991). Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol., 104, 495-503.
24. LI, F. & JOSHUA, I.G. (1993). Decreased arteriolar endothelium-derived relaxing factor production during the development of genetic hypertension. Clin. Exp. Hypertens., 15, 511-526.
25. LUSCHER, T. (1991). Endothelium-derived nitric oxide - The endogenous nitrovasodilator in the human cardiovascular system. Eur. Heart J., 12, 2-11.
26. MANGANIELLO, V.C., MURATA, T., TAIRA, M., BELFRAGE, P. & DEGERMAN, E. (1995). Diversity in cyclic nucleotide phosphodiesterase isozyme families. Arch. Biochem. Biophys., 322, 1-13.
27. MCMAHON, E., PALOMO, M., MEHTA, P., OLINS, G. (1989). Depressor and natriuretic effects of M&B 22.948, a guanosine cyclic 3′, 5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther., 251, 1000-1005.
28. MELLION, B.T., IGNARRO, L.J., OHLSTEIN, E.H., PONTECORVO, E.G., HYMAN, A.L. & KADOWITZ, P.J. (1981). Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood, 57, 946-955.
29. MERKEL, L., RIVERA, L., PERRONE, M. & LAPPE, R. (1992). In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur. J. Pharmacol., 216, 29-35.
30. MICHELI, D., COLLODEL, A., SEMERARO, C., GAVIRAGHI, G. & CARPI, C. (1990). Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies. J. Cardiovasc. Pharmacol., 15, 666-675.
31. MOCHLY-ROSEN, D. (1995). Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science, 268, 247-251.
32. MOE, G.W., CANEPA-ANSON, R. & ARMSTRONG, P.W. (1992). Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. J. Cardiovasc. Pharmacol., 19, 691-700.
33. MORITA, T., PERRELLA, M.A., LEE, ME., KOUREMBANAS, S. (1995). Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc. Natl. Acad. Sci. U.S.A., 92, 1475-1479.
34. MURAD, F. (1986). Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest., 78, 1-5.
35. NAKAMURA, M., ARAKAWA, N., YOSHIDA, H., MAKITA, S. & HIRAMORI, K. (1990). Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation, 90, 1210-1214.
36. PACKER, M. (1990). What causes tolerance to nitroglycerin?: the 100 year old mystery continues. J. Am. Coll. Cardiol., 16, 932-935.
37. PAPAPETROPOULOS, A., MARCZIN, N., SNEAD, M.D, CHENG, C., MILICI, A. & CATRAVAS, J.D. (1994). Smooth muscle cell responsiveness to nitrovasodilators in hypertensive and normotensine rats. Hypertension, 23, 476-484.
38. RUTH, P., WANG, G,X., BOEKHOFF, I., MAY, B., PFEIFER, A., PENNER, R., KORTH, M., BREER, H. & HOFMANN, F. (1993). Transfected cGMP-dependent protein kinase suppresses calcium transients by inhibition of inositol 1,4,5-triphosphate production. Proc. Natl. Acad. Sci. U.S.A., 90, 2623-2627.
39. SAEKI, T., ADACHI, H., TAKASE, Y., YOSHITAKE, S., SOUDA, S & SAITO, I. (1995). A selective type V phosphodiesterase inhibitor, E4021, dilates large porcine coronary artery. J. Pharmacol. Exp. Ther., 272, 825-831.
40. SAEKI, T. & SAITO, I. (1993). Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem. Pharmacol., 46, 833-839.
41. SAWADA, Y., SAKAMAKI, T., NAKAMURA, T., SATO, K., ONO, Z. & MURATA, K. (1994). Release of nitric oxide in response to acetylcholine is unaltered in spontaneously hypertensive rats. J. Hypertens., 12, 745-750.
42. SILVER, P.J., DUNDORE, R.J., BODE, D.C., DE GARAVILLA, L., BUCHHOLZ, R.A., VAN ALLER, G., HAMEL, L.T., BACON, E., SINGH, B., LESHER, G.Y., HLASTA, D & PAGANI, E.D. (1995). Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther., 271, 1143-1149.
43. TOMINAGA, M., EUJII, K., TAKATA, Y., KOBAYASHI, K. & FUJISHIMA, M. (1994). Hypertension and ageing impair acetylcholine-induced vasodilation in rats. J. Hypertens., 12, 259-268.
44. TRAPANI, A.J., SMITS, G.J., MCGRAW, D.E., MCMAHON, EG & BLAINE, E.H. (1991). Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther., 258, 269-274.
45. 2+ dynamics, contractility, or phospholamban phosphorylation. J. Biol. Chem., 269, 19151-19156.